VolitionRx and Sysmex Collaborate to Optimize Nu.Q NETs Assay

VolitionRx Limited (NYSE American: VNRX) is making significant strides in the diagnostics space through a strategic collaboration with Sysmex (TYO: 6869) to optimize Volition’s Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform. This partnership aligns with Volition’s licensing strategy, which aims to leverage the expertise, regulatory capabilities, and extensive installed analyzer base of established global diagnostics companies to accelerate the development and commercialization of its proprietary Nu.Q® NETs technology. The collaboration has advanced beyond the initial assay transfer phase and is now in the optimization stage for diseases associated with NETosis, a cellular process implicated in conditions such as sepsis and other acute and chronic diseases. Volition believes that the Nu.Q® NETs assay could provide enhanced diagnostic information, support patient monitoring, and address a substantial commercial opportunity with an estimated total addressable market of $3.8 billion.

Volition, a multi-national company focused on advancing epigenetics, is dedicated to saving lives and improving outcomes for people and animals through earlier detection and monitoring of life-altering diseases. Through its subsidiaries, the company develops and commercializes simple, cost-effective blood tests for detecting and monitoring a range of diseases, including certain cancers and NETosis-related conditions like sepsis. By enabling early detection and monitoring, Volition aims to prolong patients' lives and enhance their quality of life. The company’s research and development activities are based in Belgium, with an innovation lab and office in the U.S. and an office in London.

The collaboration with Sysmex marks a critical step forward in bringing the Nu.Q® NETs assay to market. For more details, the full press release is available at https://ibn.fm/TSMG4. Volition’s commitment to innovation and partnership underscores its potential to impact the diagnostics landscape significantly.